Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

October 14, 2025

Study Completion Date

October 14, 2025

Conditions

Heart Failure

Interventions

DRUG

THRV-1268

THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

DRUG

Placebo

Trial Locations (1)

RECRUITING

Dr. Vince Clinical Research, Overland Park

All Listed Sponsors

lead

Thryv Therapeutics, Inc.

INDUSTRY